share_log

UniQure Has Dosed The First Patient In GenTLE Phase 1/2a Trial Of AMT-260 For Refractory Mesial Temporal Lobe Epilepsy

UniQure Has Dosed The First Patient In GenTLE Phase 1/2a Trial Of AMT-260 For Refractory Mesial Temporal Lobe Epilepsy

UniQure已经在GenTLE阶段1/2a试验中为难治性内侧颞叶癫痫给药首位患者。
Benzinga ·  2024/11/21 20:08

UniQure Has Dosed The First Patient In GenTLE Phase 1/2a Trial Of AMT-260 For Refractory Mesial Temporal Lobe Epilepsy

UniQure已经在GenTLE阶段1/2a试验中为难治性内侧颞叶癫痫给药首位患者。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发